Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects (EMPA)
Diseases of the Cardiovascular System
What is the purpose of this trial?
The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.
- Ages18 years and older
- Trial withBoehringer Ingelheim Pharmaceuticals, Inc.
- Start Date04/18/2017
- End Date10/30/2018
- Last Updated02/22/2018
- Study HIC#2000020019